theseus: extract claims from 2026-05-04-theseus-mode5-transformation-synthesis

- Source: inbox/queue/2026-05-04-theseus-mode5-transformation-synthesis.md
- Domain: ai-alignment
- Claims: 0, Entities: 0
- Enrichments: 3
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Theseus <PIPELINE>

domains/ai-alignment/ai-governance-failure-mode-5-pre-enforcement-legislative-retreat.md

@@ -52,3 +52,10 @@ EU AI Act Omnibus trilogue demonstrates Mode 5 variant: both Council and Parliam
 **Source:** Acemoglu, Project Syndicate March 2026
 
 Acemoglu provides cross-disciplinary confirmation from institutional economics that Mode 6 (emergency exception override) shares the same governance philosophy as Mode 5: emergency exceptionalism where constraints are treated as contingent. An MIT Nobel laureate in economics reaching the same structural conclusion as alignment researchers through institutional analysis strengthens the claim that this is a general governance failure mode, not AI-specific.
+
+
+## Extending Evidence
+
+**Source:** Theseus synthetic analysis, May 4, 2026
+
+The April 28, 2026 EU AI Act Omnibus trilogue failure creates three distinct outcome paths: (A) May 13 trilogue succeeds, Omnibus passes, Mode 5 proceeds as documented (~25%); (B) May 13 fails, August 2 passes unenforced with Commission transitional guidance, creating Mode 5 Variant B through administrative discretion rather than legislative pre-emption (~50%); (C) May 13 fails, Commission enforces at least partially, representing B1's first genuine disconfirmation test from governance side (~25%). The trilogue failure on structural disagreement over Annex I conformity assessment architecture was not widely anticipated in Sessions 38-42.

domains/ai-alignment/alignment-tax-operates-as-market-clearing-mechanism-across-three-frontier-labs.md

@@ -24,3 +24,10 @@ The Google-Pentagon deal provides the third empirical data point confirming the
 **Source:** The Intercept, March 8 2026
 
 OpenAI accepted Tier 3 DoD terms ('any lawful use') with stated red lines that are structurally non-enforceable in classified deployments, while Anthropic held to 'no autonomous weapons, no domestic surveillance' and lost the contract (resulting in supply chain designation). This confirms the alignment tax pattern: Anthropic paid the tax (lost the contract), OpenAI avoided the tax (accepted the contract with nominal restrictions that cannot be verified).
+
+
+## Extending Evidence
+
+**Source:** Theseus synthetic analysis, May 4, 2026
+
+The April 28, 2026 dual-event pattern (EU Omnibus failure making civilian AI enforcement potentially active + Google Pentagon deal on same day) suggests complementary governance dynamics: EU civilian AI governance becoming potentially enforceable for the first time, while US military AI governance shows safety-constrained labs blacklisted as unconstrained labs get contracts. The EU's military exclusion gap means even successful civilian enforcement would not constrain Pentagon-Google-OpenAI classified AI deployments that are the most consequential current governance failure, demonstrating that the alignment tax mechanism operates outside EU AI Act scope by design.

domains/ai-alignment/voluntary-safety-constraints-without-enforcement-are-statements-of-intent-not-binding-governance.md

@@ -12,7 +12,7 @@ sourcer: The Intercept
 related_claims: ["voluntary-safety-pledges-cannot-survive-competitive-pressure", "[[the alignment tax creates a structural race to the bottom because safety training costs capability and rational competitors skip it]]"]
 supports: ["Voluntary AI safety constraints are protected as corporate speech but unenforceable as safety requirements, creating legal mechanism gap when primary demand-side actor seeks safety-unconstrained providers"]
 reweave_edges: ["Voluntary AI safety constraints are protected as corporate speech but unenforceable as safety requirements, creating legal mechanism gap when primary demand-side actor seeks safety-unconstrained providers|supports|2026-04-20"]
-related: ["voluntary-safety-constraints-without-enforcement-are-statements-of-intent-not-binding-governance", "voluntary-safety-constraints-without-external-enforcement-are-statements-of-intent-not-binding-governance", "multilateral-verification-mechanisms-can-substitute-for-failed-voluntary-commitments-when-binding-enforcement-replaces-unilateral-sacrifice", "voluntary-ai-safety-constraints-lack-legal-enforcement-mechanism-when-primary-customer-demands-safety-unconstrained-alternatives", "government-safety-penalties-invert-regulatory-incentives-by-blacklisting-cautious-actors", "voluntary-ai-safety-red-lines-are-structurally-equivalent-to-no-red-lines-when-lacking-constitutional-protection", "advisory-safety-language-with-contractual-adjustment-obligations-constitutes-governance-form-without-enforcement-mechanism"]
+related: ["voluntary-safety-constraints-without-enforcement-are-statements-of-intent-not-binding-governance", "voluntary-safety-constraints-without-external-enforcement-are-statements-of-intent-not-binding-governance", "multilateral-verification-mechanisms-can-substitute-for-failed-voluntary-commitments-when-binding-enforcement-replaces-unilateral-sacrifice", "voluntary-ai-safety-constraints-lack-legal-enforcement-mechanism-when-primary-customer-demands-safety-unconstrained-alternatives", "government-safety-penalties-invert-regulatory-incentives-by-blacklisting-cautious-actors", "voluntary-ai-safety-red-lines-are-structurally-equivalent-to-no-red-lines-when-lacking-constitutional-protection", "advisory-safety-language-with-contractual-adjustment-obligations-constitutes-governance-form-without-enforcement-mechanism", "trust-based-safety-guarantees-fail-architecturally-in-classified-deployments"]
 ---
 
 # Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility
@@ -66,3 +66,10 @@ Taxonomy shows voluntary constraints fail through four mechanistically distinct
 **Source:** Theseus Session 40, EU AI Act Omnibus deferral April 28, 2026
 
 The EU AI Act Omnibus deferral extends this pattern from voluntary commitments to mandatory legislative constraints. Even binding hard law enacted by democratic legislature is being preemptively weakened before enforcement can test its effectiveness, suggesting the structural pressures that erode voluntary commitments also operate at the legislative level.
+
+
+## Extending Evidence
+
+**Source:** Theseus synthetic analysis, May 4, 2026
+
+The EU AI Act's August 2, 2026 enforcement deadline represents the first time in AI governance history that mandatory enforcement is legally in force without a confirmed delay mechanism, following the April 28, 2026 Omnibus trilogue failure. This creates a natural experiment testing whether mandatory mechanisms can work for civilian high-risk AI systems (medical devices, credit scoring, recruitment, critical infrastructure), though the Act's explicit military exclusion means the most consequential AI deployments (classified military systems) remain outside mandatory governance scope by design.

domains/health/glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure.md

@@ -24,3 +24,10 @@ Converging evidence from multiple 2025-2026 trials reveals a clear anatomical pa
 **Source:** Exenatide-PD3 Phase 3 RCT, Lancet February 2025
 
 Exenatide Phase 3 trial (n=194, 96 weeks) failed all endpoints in Parkinson's disease: no motor benefit, no non-motor benefit, and critically, DaT-SPECT imaging showed zero dopaminergic neuroprotection signal. CSF analysis revealed insufficient drug penetration to substantia nigra despite exenatide crossing the BBB in other brain regions. This confirms the circuit-specificity principle: GLP-1 agonists succeed in reward/dopamine circuits (SUD, MDD) but fail in neurodegenerative contexts where the mechanism is protein aggregation (α-synuclein) rather than reward dysregulation.
+
+
+## Supporting Evidence
+
+**Source:** NBC News synthesis April 2026, Session 22 Science 2025
+
+GLP-1 receptor expression in ventral tegmental area (VTA) and nucleus accumbens (NAc) enables reward circuit modulation across multiple substance classes. Session 22 Science 2025 paper confirmed VTA dopamine circuit adaptation during repeat GLP-1 treatment (mice recover hedonic eating), suggesting efficacy may fade with long-term use for some reward circuits. This shared VTA dopamine mechanism explains why GLP-1 effects generalize across AUD, OUD, nicotine, and food reward — all operate through the same mesolimbic pathway.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -171,3 +171,10 @@ Contradictory animal evidence on dopamine mechanism: one lab found 'chronically
 **Source:** JAMA Psychiatry RCT + PMC systematic review
 
 Semaglutide + CBT for AUD achieved 41.1% reduction in heavy drinking days with NNT 4.3 (vs. 7+ for approved AUD medications) in double-blind RCT (N=108). Mechanistic hypothesis: GLP-1 reduces reward salience through mesolimbic dopamine modulation, beneficial for addiction/cravings. However, this same mechanism may reduce hedonic response broadly, potentially explaining the 195% MDD risk signal in observational cohort data.
+
+
+## Extending Evidence
+
+**Source:** NBC News/Pharmacy Times synthesis April 2026, Session 22 Science 2025 VTA dopamine circuit paper
+
+GLP-1 receptor agonists show evidence across multiple substance use disorders beyond AUD: (1) Opioid Use Disorder: liraglutide produced ~40% reduction in opioid craving in small RCT; semaglutide significantly reduced opioid overdose risk in 1-year follow-up for T2D+OUD patients (real-world data). (2) Nicotine: exenatide + NRT increased 7-day abstinence vs placebo at week 6, though long-term findings mixed; SEMALCO trial showed reduced cigarettes/day as secondary endpoint in AUD+smoking subgroup. (3) Cocaine/stimulants: liraglutide reduces operant methamphetamine intake in rats (preclinical only). Population-level evidence: among people with pre-existing SUD on GLP-1s, fewer ER visits, hospitalizations, and deaths across substance categories (observational data). As of April 2026: 33 clinical trials for SUD (15 AUD, 9 nicotine, 4 OUD, 4 cocaine). Evidence strength hierarchy: AUD > OUD > nicotine > cocaine.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -12,7 +12,7 @@ scope: causal
 sourcer: NIH / JAMA Psychiatry
 supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
 challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions"]
+related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "semaglutide-demonstrates-superior-aud-efficacy-to-all-approved-medications-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients"]
 ---
 
 # GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
@@ -39,3 +39,10 @@ Meta-analysis demonstrates effect extends beyond comorbid obesity population to
 **Source:** VigiBase study, Clinical Nutrition 2025
 
 VigiBase pharmacovigilance analysis shows eating disorder signals with aROR 4.17-6.80 across all three GLP-1 RAs (semaglutide, dulaglutide, liraglutide), suggesting GLP-1's appetite suppression mechanism may precipitate eating disorder pathology in vulnerable individuals. This is a class effect, not drug-specific, indicating the reward pathway modulation that benefits AUD may create eating disorder risk in susceptible populations.
+
+
+## Extending Evidence
+
+**Source:** NBC News/Pharmacy Times April 2026
+
+Critical limitation applies across all SUD evidence: all human data comes from patients with comorbid metabolic disease (T2D or obesity). Whether GLP-1s work for SUD without metabolic comorbidity is unknown and largely unstudied. This constraint affects not just AUD but the entire SUD evidence base — OUD, nicotine, and cocaine trials all recruit from metabolically compromised populations.

inbox/archive/ai-alignment/2026-05-04-theseus-mode5-transformation-synthesis.md

@@ -7,10 +7,13 @@ date: 2026-05-04
 domain: ai-alignment
 secondary_domains: [grand-strategy]
 format: synthetic-analysis
-status: unprocessed
+status: processed
+processed_by: theseus
+processed_date: 2026-05-08
 priority: medium
 tags: [Mode-5, EU-AI-Act, enforcement, governance-failure, mandatory-mechanism, August-2026, military-exclusion, Mode5-variant, B1-disconfirmation]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2026-05-03-glp1-addiction-scope-oud-nicotine-cocaine-synthesis.md

@@ -7,10 +7,13 @@ date: 2026-04-28
 domain: health
 secondary_domains: []
 format: news-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-05-08
 priority: medium
 tags: [GLP-1, addiction, opioid-use-disorder, nicotine, cocaine, substance-use-disorder, VTA-dopamine, reward-mechanism]
 intake_tier: research-task
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content